Protection in specific-pathogen-free chickens with live avian metapneumovirus and Newcastle disease virus vaccines applied singly or in combination 
Summary
This paper describes two experiments. In each, day-old specific pathogen free (SPF) chicks were divided into three groups. In Experiment 1 [avian metapneumovirus virus (aMPV) challenge], one group served as unvaccinated controls; the second group was vaccinated with live aMPV (subtype B) vaccine only and the third group received the aMPV vaccine in combination with live Newcastle disease virus (NDV) vaccine (VG/GA strain).
Oropharyngeal swabs, tissues and blood samples were collected before and after challenge with a virulent subtype aMPV at 21 days post vaccination (d.p.v.) . Chicks were monitored for post challenge clinical signs. Swabs and tissues were examined for the detection of challenge aMPV by isolation (VI) and by reverse-transcriptase polymerase-chain reaction (RT-PCR). Sera were assayed for antibodies against aMPV and NDV. The single and combined vaccinated chicks were all protected against clinical signs and no challenge virus was isolated from either of the vaccinated -challenged groups. In Experiment 2 (NDV challenge), as in the Experiment 1, chicks were divided into three groups where one group remained as unvaccinated control and the other two groups were vaccinated as above, except that the second group received live NDV vaccine only, instead of aMPV. 
Introduction
Turkey rhinotracheitis (TRT) is an important respiratory disease in turkeys caused by avian metapneumovirus (aMPV), and in chicks, the virus is sometimes associated with swollen head syndrome (SHS) (Cook & Cavanagh, 2002; Cook, 2000) . Newcastle disease is caused by paramyxovirus serotype 1 (APMV-1) and is an economically important disease worldwide in chickens and turkeys (Alexander & Jones, 2001; Alexander, 2003) . Live and inactivated vaccines are used to prevent both of these diseases (Alexander & Jones, 2001; Alexander, 2003) .
The interactions between live aMPV and Newcastle disease virus (NDV) vaccines when given simultaneously in SPF chicks were reported by Ganapathy et al. (2005) . The In those experiments, no challenge was carried out to assess protection against virulent aMPV or NDV. This paper reports on the protection conferred by aMPV (NEMOVAC®) or NDV (AVINEW®) vaccines applied singly or dually in White-Leghorn specific pathogen free (SPF) chicks against virulent aMPV or NDV challenge.
Materials and Methods
Chickens. In each of the two experiments, White Leghorn day-old SPF chicks (Lohmann Animal Health, Cuxhaven, Germany) were randomly allocated into three groups and were Vaccines. As in the previous report (Ganapathy et al., 2005) , commercial vaccines of NDV (AVINEW®) and avian metapneumovirus (NEMOVAC®) were used. The vaccine reconstitution and mixture preparation were the same as described (Ganapathy et al., 2005) .
The dosages of vaccines are given in Table 1 .
Experimental design. Two experiments were carried out. In each experiment, chicks were allocated into three groups (Table 1) .
Experiment 1 (aMPV challenge).
Chicks were randomly allocated to three groups of 24 each (Table 1) from each group were transferred to another isolation room, and challenged with virulent aMPV (subtype B), which was propagated in tracheal organ cultures (TOCs) and the virus titre determined using the same culture system. TOCs were prepared from SPF chick embryos after 19-20 days incubation following the method of Cook et al. (Cook et al., 1976) .
Each bird received 0.1 ml of 4.5 log 10 median ciliostatic doses 50 (CD 50 ) of the challenge virus via the ocular route.
Post-challenge clinical signs:
After challenge, birds were monitored daily for clinical signs and the severity of the clinical signs was scored as described by Jones et al. (1992) . Briefly, a 
Oropharyngeal (OP) swabs:
Prior to challenge, 10 OP swabs were collected from each group. After challenge, oropharyngeal samples were obtained from 8 chicks in each group at 3, 6 and 9 days post challenge (d.p.c.) using dry swabs. In addition, another set of swabs was taken from the same chicks but using swabs previously moistened in TOC medium [Eagles serum-free MEM with glutamine, streptomycin (50 µg/ml) and penicillin (50 IU/ml)]. OP swabs were also randomly collected from the unchallenged groups but only from 5 chicks.
The dry and wet swabs were processed for RT-PCR and virus isolation respectively. Swabs from the challenged birds were processed individually whilst the other swabs were pooled.
Sera: Blood samples were obtained at 21 days (pre-challenge) and 32 days (10 days postchallenge) of age from 8 chicks per group for detection of antibodies against aMPV and NDV.
Tissues: At 7d.p.v. and at 5 and 10 d.p.c., four birds per group were humanely killed and pieces of turbinate, trachea and lung were collected for aMPV RT-PCR and virus isolation.
Experiment 2 (NDV challenge).
The grouping was the same as Experiment 1 except that chicks in the single vaccination group received live NDV, instead of aMPV vaccine. The volume and administration of inocula were the same as described above and the dosages per bird are shown in (Cook et al., 1976; Ganapathy et al., 2005) . OP swabs and tissues were also examined for aMPV by RT-PCR as described (Ganapathy et al., 2005) .
Detection of vaccinal antibodies. NDV antibodies were detected by haemagglutinationinhibition (HI) (Allan & Gough, 1974) . For aMPV antibodies, sera were tested by an inhouse ELISA as described by Worthington et al. (2003) , but the coating antigen was subtype B aMPV (Ganapathy et al., 2005) . In both assays, the mean titre at each sampling point was calculated. For aMPV ELISA, titres above 6 (log 2 ) are considered significant for the presence of the aMPV antibodies.
Statistics. The mean antibody titres at each sampling point were compared using a Student's t-test. 
Results

Clinical signs and post mortem lesions. Experiment 1 (aMPV challenge
Experiment 2 (NDV challenge).
In the Unvac-Ch chicks, signs of dullness, depression, ruffled feathers, watery eyes, inappetence and paralysis were recorded 3 days after NDV challenge. All birds in this group died or were humanely killed by 7 d.p.c. Chicks in the NDV-vaccinated groups showed no clinical signs and none died. No necropsy was carried out.
Detection of a MPV virus. Experiment 1 (aMPV challenge).
All OP swabs from the unvaccinated, aMPV and aMPV+NDV-vaccinated birds were negative for aMPV by RT-PCR and VI (data not shown). For the Unvac-Ch birds, 8, 7 and 8 swabs were positive for aMPV at 3, 6 and 9 d.p.c. respectively by RT-PCR but virus was isolated from all swabs at 3 d.p.c. but not later (Table 2 ). In the aMPV-Ch and aMPV+NDV-Ch chicks, 7 and 8 swabs respectively were RT-PCR positive at 3 and 6 d.p.c., and this was reduced to 3 or 4 at 9 d.p.c.
All of these swabs were negative by VI.
When the tissues were examined, no virus was detected in the trachea in any group by either method. Using RT-PCR virus was detected in turbinates (5 and 10 days) in the UnvacCh group (Table 3) . Both of the other groups were negative. 
Serology. Experiment 1 (aMPV challenge).
There were no significant differences in the prechallenge aMPV ELISA antibody titres between the aMPV-vaccinated groups (Table 3 ). The post-challenge antibody titres in each group were significantly higher than the respective unchallenged groups.
For NDV, HI titres in the control and single aMPV-vaccinated groups remained below the detectable level (Table 3 ). In the combined vaccination group, there were no significant differences in the pre or post aMPV-challenged NDV HI titres.
Experiment 2 (NDV challenge).
For NDV HI antibodies, at 21 d.p.v. (pre-challenge) the titre remained below detectable level in the unvaccinated group (Table 3) and there were no significant differences between the two NDV-vaccinated groups. The post-challenge antibody titres in each group were significantly higher than the respective unchallenged groups.
For aMPV ELISA antibodies, there were no significant differences in the pre (7.90±1.56) and post (9.27±0.97) NDV-challenge titres in the simultaneously vaccinated chicks.
Discussion
This study was designed to complement our previous work (Ganapathy et al., 2005) where interactions between live aMPV and NDV vaccine viruses in SPF chicks were examined. In that work, systemic vaccine virus distribution and immune responses were studied but no challenge was carried out with virulent aMPV or NDV. From findings reported in this paper, As for NDV, no clinical signs or mortality were seen in NDV-vaccinated chicks (alone or dually with aMPV) but all the unvaccinated-challenged chicks died or were humanely killed (due to illness) within 7 days of challenge. This result shows that irrespective of single or dual NDV vaccination, complete protection was induced against virulent NDV challenge.
With respect to the serological results, in contrast to our previous study (Ganapathy et al., 2005) , between the single and dual vaccinated groups, there were no significant differences in the levels of antibodies with respect to each vaccine. The reasons for this discrepancy are not clear but factors such as group size (larger here compare to the small and reducing numbers in the previous work), perhaps the male-female ratio (unknown in both) and other unknown factors may have influenced the outcome. For aMPV, previous studies have emphasized that local and cell mediated immune responses are important in resisting and clearing the virus (Cook et al., 1989; Jones et al., 1992; Khehra et al., 1999; Ganapathy et al., 2005) . For NDV, levels of protection closely correlate with the levels of humoral HI antibodies (Alexender, 2003) . In this study, at the time of NDV challenge, the mean NDV HI 
